Physician profile
Gregory M Loewen
NPI 1306836499
$6,222.40
in general payments reported to CMS, 2019-2025
25 companies · $118 in 2025
The $118 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,539 · 2020: $82.74 · 2021: $501 · 2022: $394 · 2023: $420 · 2024: $169 · 2025: $118.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $706.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Laboratories INC. | $3,600.00 | 2019 | |
| Glaxosmithkline, LLC. | $618.84 | 2019-2023 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $500.84 | 2019-2023 | Tezspire, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $320.07 | 2019-2023 | Ofev |
| Janssen Pharmaceuticals, INC | $262.39 | 2024-2025 | Spravato |
| Grifols USA, LLC | $193.69 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $102.85 | 2019-2023 | Dupixent |
| Genzyme Corporation | $101.86 | 2019-2023 | |
| Electromed, INC. | $78.07 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $72.91 | 2019-2024 | Opsumit, Uptravi |
| Mylan Specialty L.P. | $59.32 | 2019-2023 | Yupelri |
| Sunovion Pharmaceuticals INC. | $36.91 | 2019 | |
| Philips North America LLC | $33.27 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $29.40 | 2021 | |
| Mallinckrodt Enterprises LLC | $26.99 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $26.42 | 2019 | |
| Atricure, INC. | $20.59 | 2023 | |
| Genentech USA, INC. | $20.58 | 2019 | |
| Vapotherm INC | $20.05 | 2019 | |
| Insmed, INC. | $19.51 | 2023 | Arikayce |
| Astellas Pharma US INC | $18.36 | 2019 | |
| United Therapeutics Corporation | $18.08 | 2021 | |
| Gilead Sciences, INC. | $15.23 | 2023 | Veklury |
| Jazz Pharmaceuticals INC. | $13.35 | 2021 | |
| Mallinckrodt Hospital Products INC. | $12.82 | 2023 | Acthar |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Loewen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.